Aristotle University Of Thessaloniki (AUTH)
Η αξιολόγηση της επίδρασης των αναστολέων του συμμεταφορέα γλυκόζης-νατρίου τύπου 2 στην αορτική σκληρία και τη λειτουργία της δεξιάς κοιλίας σε ασθενείς με σακχαρώδη διαβήτη τύπου 2
Abstract
dc:descriptionOBJECTIVE: The aim of the present observational study was to assess the effect of long-term SGLT-2 inhibitor treatment on ambulatory arterial stiffness and right ventricular (RV) function. MATERIAL AND METHODS: The present study was conducted from August 2019 to August 2021 in the Diabetes Centre of the Second Propaedeutic Department of Internal Medicine in General Hospital of Thessaloniki “Ippokrateio”. In total, 46 adult subjects with T2DM and stable antidiabetic and antihypertensive medication for the last 6 months were enrolled. Twenty of them also underwent echocardiography for the evaluation of the impact of SGLT-2 inhibitors on RV function. Patients were informed about the research protocol and relevant examinations and participated after providing a written informed consent. Patients were prescribed either empagliflozin or dapagliflozin, according to treating physician’s clinical discretion. RESULTS: Regarding the arterial stiffness assessment study, 46 patients with T2DM, with a mean age of 62.89 ± 8.53 years and a mean T2DM duration of 9.72 ± 6.37 years were recruited. Mean duration of treatment was 9.98 ± 3.27 months. Thirty patients received dapagliflozin, while 16 patients received empagliflozin. It was demonstrated that SGLT-2 inhibitors resulted in a non-significant decrease in PWV (p = 0.65); SGLT-2 inhibitors produced a non-significant decrease in daytime PWV (p = 0.7) and a non-significant increase in nighttime PWV (p = 0.32). History of established cardiovascular disease did not significantly affect the observed effects. Other markers of ambulatory arterial stiffness, such as augmentation index and central pulse pressure, were also not significantly affected, despite being numerically decreased. Regarding the echocardiographic study, 20 patients with T2DM (mean age of 62.8 ± 7.87 years and mean T2DM duration of 8.7 ± 6.12 years) were enrolled. Mean treatment duration was 9.35 ± 3.4 months. Thirteen patients received dapagliflozin, while the remaining 7 received empagliflozin. In total, SGLT-2 inhibitors led to a significant improvement in RV systolic function, as tricuspid annular plane systolic excursion (TAPSE) increased from 2.01 ± 0.23 to 2.12 ± 0.15 cm (p = 0.022). Of note, the observed benefit was important only for those patients with concomitant cardiovascular disease. RV diastolic function and RV dimensions were not significantly affected. Concerning the rest efficacy outcomes of interest, a significant increase in hematocrit and hemoglobin levels, along with a significant increase in high-density lipoprotein cholesterol levels was observed after treatment with SGLT-2 inhibitors. However, SGLT-2 inhibitors treatment did not have a significant effect on other parameters of interest, such as 24-h and office blood pressure levels, along with the remaining lipid parameters, 24-h urine protein excretion, serum uric acid and C-reactive protein levels. No serious adverse events were observed. CONCLUSIONS: The present study failed to demonstrate a significant effect of empagliflozin and dapagliflozin on ambulatory arterial stiffness indices among patients with T2DM and either established cardiovascular disease or multiple cardiovascular risk factors. Thus, at present, we cannot adopt the opinion that cardio-protection observed with SGLT-2 inhibitors is partially mediated by improvement in arterial stiffness, based also on the fact that in the trials reaching statistical significance, numeric change in PWV was too small. However, we showed a significant improvement in systolic RV function, a finding that should be highlighted, although it must be confirmed in large-scale trials.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Patoulias, Dimitrios
- Πατουλιάς, Δημήτριος
Subjects
dc:subject × 16- Αναστολέας συμμεταφορέα γλυκόζης-νατρίου τύπου 2
- Αρτηριακή σκληρία
- Καρδιαγγειακή νόσος
- Σακχαρώδης διαβήτης τύπου 2
- Sodium-glucose co-transporter 2 inhibitor
- Arterial stiffness
- Cardiovascular disease
- Type 2 diabetes mellitus
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Καρδιολογία και Καρδιοαγγειακά νοσήματα
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51462